BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19261537)

  • 1. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease.
    Monteleone G; Pallone F; Macdonald TT
    Cytokine Growth Factor Rev; 2009 Apr; 20(2):185-91. PubMed ID: 19261537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-21 as a new therapeutic target for immune-mediated diseases.
    Monteleone G; Pallone F; Macdonald TT
    Trends Pharmacol Sci; 2009 Aug; 30(8):441-7. PubMed ID: 19616319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-21 in T cell-mediated diseases.
    Monteleone G; Sarra M; Pallone F
    Discov Med; 2009 Oct; 8(42):113-7. PubMed ID: 19833056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells.
    Chen H; Qin J; Wei P; Zhang J; Li Q; Fu L; Li S; Ma C; Cong B
    Prostaglandins Leukot Essent Fatty Acids; 2009 Apr; 80(4):195-200. PubMed ID: 19264469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th17 cells: a new paradigm for cutaneous inflammation.
    Asarch A; Barak O; Loo DS; Gottlieb AB
    J Dermatolog Treat; 2008; 19(5):259-66. PubMed ID: 18629676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo.
    Gyülvészi G; Haak S; Becher B
    Eur J Immunol; 2009 Jul; 39(7):1864-9. PubMed ID: 19544494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice.
    Jang E; Cho SH; Park H; Paik DJ; Kim JM; Youn J
    J Immunol; 2009 Apr; 182(8):4649-56. PubMed ID: 19342640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.
    González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
    Arthritis Rheum; 2009 Apr; 60(4):1006-19. PubMed ID: 19333946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma.
    Deleuran B; Abraham DJ
    Nat Clin Pract Rheumatol; 2007 Dec; 3(12):682-3. PubMed ID: 17848933
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-21 in chronic inflammatory diseases.
    Sarra M; Pallone F; Monteleone G
    Biofactors; 2013; 39(4):368-73. PubMed ID: 23553807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-21: a new modulator of immunity, infection, and cancer.
    Brandt K; Singh PB; Bulfone-Paus S; Rückert R
    Cytokine Growth Factor Rev; 2007; 18(3-4):223-32. PubMed ID: 17509926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus.
    Yang J; Chu Y; Yang X; Gao D; Zhu L; Yang X; Wan L; Li M
    Arthritis Rheum; 2009 May; 60(5):1472-83. PubMed ID: 19404966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.
    Huber M; Heink S; Grothe H; Guralnik A; Reinhard K; Elflein K; Hünig T; Mittrücker HW; Brüstle A; Kamradt T; Lohoff M
    Eur J Immunol; 2009 Jul; 39(7):1716-25. PubMed ID: 19544308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive immunity in inflammatory bowel disease: state of the art.
    Kaser A; Blumberg RS
    Curr Opin Gastroenterol; 2008 Jul; 24(4):455-61. PubMed ID: 18622159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
    Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
    J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation.
    Pierau M; Engelmann S; Reinhold D; Lapp T; Schraven B; Bommhardt UH
    J Immunol; 2009 Nov; 183(10):6124-34. PubMed ID: 19841181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells.
    Wolk K; Sabat R
    Cytokine Growth Factor Rev; 2006 Oct; 17(5):367-80. PubMed ID: 17030002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.
    Sutton CE; Lalor SJ; Sweeney CM; Brereton CF; Lavelle EC; Mills KH
    Immunity; 2009 Aug; 31(2):331-41. PubMed ID: 19682929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.